Homodimeric antibodies for the treatment of cancer and uses thereof
The homodimeric antibody formed by covalent cross-linking solves the problems of limited efficacy and long infusion time of existing therapeutic antibodies in cancer treatment, achieving stronger cancer cell killing activity and shorter infusion time, reducing non-specific side effects, and enhancing the effect of cancer treatment.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- MEDICAL SCIENCE CO
- Filing Date
- 2024-10-18
- Publication Date
- 2026-07-17
AI Technical Summary
Existing therapeutic antibodies have limitations in cancer treatment, including limited efficacy, long infusion times, restricted Fc receptor-mediated cytotoxicity, and non-specific side effects. In particular, the potential of homodimeric antibodies has not been fully recognized.
Homodimeric antibodies are used, and the dimers formed by covalent cross-linking increase the antigen binding sites, improve pharmacokinetics and affinity, and utilize endocytosis and drug conjugates to achieve cancer cell endocytosis and cell death, reduce Fc receptor-mediated dependence, and design flexible linkers to maintain Fc receptor accessibility.
Homodimeric antibodies exhibit stronger cancer cell killing activity, shorter infusion time, reduced non-specific side effects, improved cancer cell binding efficiency, and enhanced therapeutic efficacy, especially showing excellent results in cancers targeting low copy number antigen expression.
Smart Images
Figure CN122422355A_ABST